Arrowhead Pharmaceuticals, Inc. (ARWR)

Market Cap	8.77B
Revenue (ttm)	829.45M
Net Income (ttm)	-1.63M
Shares Out	137.43M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,573,253
Open	66.45
Previous Close	66.25
Day's Range	63.69 - 66.73
52-Week Range	9.57 - 76.76
Beta	1.22
Analysts	Strong Buy
Price Target	73.70 (+15.45%)
Earnings Date	Feb 9, 2026

About ARWR

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 16, 1993
• Employees: 711
• Stock Exchange: NASDAQ
• Ticker Symbol: ARWR
• Website: https://arrowheadpharma.com

Financial Performance

In 2025, Arrowhead Pharmaceuticals's revenue was $829.45 million, an increase of 23258.15% compared to the previous year's $3.55 million. Losses were -$1.63 million, -99.73% less than in 2024.

Analyst Summary

According to 10 analysts, the average rating for ARWR stock is "Strong Buy." The 12-month stock price target is $73.7, which is an increase of 15.45% from the latest price.

Price Target

$73.7

(15.45% upside)

Analyst Consensus: Strong Buy